Pharma C Investments - Publication of Accounts
20/12/2023 14:10
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231220:nRST5073Xa&default-theme=true
RNS Number : 5073X Pharma C Investments PLC 20 December 2023
The information contained within this announcement is deemed by the Company to
constitute inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014, as retained as part of the law of England and Wales. Upon
the publication of this announcement via the Regulatory Information Service,
this inside information is now considered to be in the public domain.
20 December 2023
Pharma C Investments PLC
("Pharma C" or the "Company")
Publication of Accounts
Pharma C (AQSE: PCIL) is pleased to announce the publication of its audited
financial statements for the year ended 31 December 2022 which are available
to view and download from the Investor Relations section of the Company's
website at https://www.pharmacinvestments.com/investors/reports-presentations
(https://www.pharmacinvestments.com/investors/reports-presentations) . The
Company will call its Annual General Meeting in due course.
The Directors of Pharma C take responsibility for this announcement.
For further information please visit www.pharmacinvestments.com
(http://www.pharmacinvestments.com)
Pharma C Investments
Gavin Sathianathan Via First Sentinel
First Sentinel Corporate Finance
Brian Stockbridge, Corporate Adviser +44 20 3855 5551
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXFEAFLSEDSESE